Standardised quantitative radioiodine SPECT/CT Imaging for multicentre dosimetry trials in molecular radiotherapy
Rebecca Gregory(Barts Health NHS Trust), Glenn Flux(Royal Marsden NHS Foundation Trust), Jonathan Wadsley(Weston Park Cancer Centre), Aida Hallam(Oxford University Hospitals NHS Trust), Darren Morgan(Oxford University Hospitals NHS Trust), Iain Murray(Royal Marsden NHS Foundation Trust), Jonathan Gear(Institute of Cancer Research), Nathan Dickinson(Nottingham University Hospitals NHS Trust), Anthony J. Gill(The University of Sydney), Andrew Fenwick(National Physical Laboratory), Heather Polydor(University Hospitals Bristol NHS Foundation Trust), Sarah Chittenden(Royal Marsden NHS Foundation Trust), Francesca Leek(Royal Marsden NHS Foundation Trust), Matthew Guy(University Hospital Southampton NHS Foundation Trust), Sarah Brown(University of Leeds), Martha Stuffins(Royal Surrey County Hospital), Sofia Michopoulou(University Hospital Southampton NHS Foundation Trust), James Scuffham(Royal Surrey County Hospital), Brian Murby(The Christie NHS Foundation Trust), Colin J. Brown(Simon Fraser University), David Hall(The Open University), Jill Wevrett(National Physical Laboratory), Steve Jeans(The Christie NHS Foundation Trust), Jill Tipping(The Christie NHS Foundation Trust)
Cited by 48
Related Papers
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study
|The Lancet Oncology|2019|1.2k
BrainNetCNN: Convolutional neural networks for brain networks; towards predicting neurodevelopment
|NeuroImage|2016|782
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial
|The Lancet Oncology|2013|728
Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma
|Cancer Cell|2016|665